Cancer 2000: Vol 89 Index

33 Pages·2000·7.5 MB·English

Subject Index—Volume 89
. 1, July 1, pp. 1-228 . 8, October 15, pp. 1647-1868
. 2, July 15, pp. 229-474 . 9, November 1, pp. 1869-2024
. 3, August 1, pp. 475-714 . 10, November 15, pp. 2025-2144
. 4, August 15, pp. 715-938 . 11, December 1, pp. 2145-2326
. 5, September 1, pp. 939-1180 . 11, December 1, Supplement, pp. 2327-
. 6, September 15, pp. 1181-1412 2514
. 7, October 1, pp. 1413-1646 No. 12, December 15, pp. 2515-2686
A anti-CD20, for cutaneous B-cell lymphoma, 1835
Acquired immunodeficiency syndrome, non-Hodgkin’s monoclonal
lymphoma in, stem cell transplant for, 680 IMC-C225, inhibition of pancreatic tumor growth by,
Acute leukemia. See Leukemia 74
Adenocarcinoma. See specific sites for prostate cancer, 1329
Africa, Ivory Coast, cancer incidence in, 653 single chain Fv fragment of, in immunofluorescent
African Americans tumor localization, 1134
bladder cancer in, stage at diagnosis of, 1349 p53, in esophageal cancer, 1677
breast cancer outcome in, 2202 Anti-CD20 antibody, for cutaneous B-cell lymphoma,
AIDS, non-Hodgkin’s lymphoma in, stem cell transplant 1835
for, 680 Antiemetics, ganisetron vs. ondansetron as, 2301
Alcohol use/abuse Antiestrogen ICI 182,780 (Faslodex), for breast cancer,
gastric cancer survival and, 1205 817
hepatitis C-related hepatocellular carcinoma and, 53 Antigen(s). See also specific antigens
Alliance for Lung Cancer Advocacy, Support, and Educa- CA 19-9, in pancreatic cancer, vs. tissue polypeptide
tion (ALCASE), 2510 specific antigen, 83
Alternative therapies, compliance with standard treat- CA 125, in fallopian tube cancer, prognosis and, 1555
ment and, 873 carcinoembryonic
Alveolar proteinosis, in BCR/ABL negative chronic my- in colorectal cancer, prognosis and, 970
eloid leukemia, neutrophil hyperfunction in, 561 in immunoscintigraphy, for breast cancer, 104
Amenorrhea, after chemotherapy, for osteosarcoma, 1961 isolated elevation of, in colorectal cancer, radioim-
American Cancer Society, prospective cohort study of
munoguided surgery for, 1692
thyroid cancer, 202
Ki-67
American College of Surgeons Commission on Cancer,
in breast cancer
prospective cohort study of thyroid cancer, 202
chemotherapy response and, 2145
American Indians, stage at diagnosis, treatment, and sur-
prognosis and, 1748
vival in, 181
in Ewing’s sarcoma, prognosis and, 783
9-Aminocamptothecin, for metastatic colorectal cancer,
in nonsmall cell lung cancer, postoperative survival
1699
and, 1457
Analgesia
consultation for, outcome of, 920 p21
in bladder cancer, prognosis and, 619
morphine in hospice setting and, 220 (letter)
Angiogenesis, inhibition of in cervical squamous cell carcinoma, 1300
gene therapy for, 1181 in Ewing’s sarcoma, prognosis and, 783
p27*'P', in gastric cancer, prognosis and, 1684, 2247
for prostate cancer, 1329
Angiosarcoma, schwannoma with, 1577 p53. See p53
Angiotrophic large cell lymphoma, superior vena cava proliferating cell nuclear
syndrome and, 2515 in congenital sacrococcygeal teratoma, 932
Antiangiogenic therapy in verrucous oral cancer, 2597
gene therapy in, 1181 prostate specific
for prostate cancer, 1181, 1329 adjusted for transition zone volume, 842
Antibody(ies) after radical prostatectomy, 1810
bmiv CANCER December 15, 2000 / Volume 89 / Number 12
prostate specific membrane, monoclonal antibodies to, Benign central neurocytoma, 1111
for prostate cancer, 1329 Bile ducts, noninvasive/minimally invasive papillary car-
tissue polypeptide specific, in pancreatic cancer, 83 cinoma of, 508
Antimicrotubule drugs, for hepatoma, 983 Biliary obstruction, from gastric cancer, chemoradiation
Antioxidant enzymes, in prostatic intraepithelial neopla- for, 29
sia and cancer, 123 Biliary papillomatosis, intraluminal iridium-192 for, 69
Apoptosis, in breast cancer, chemotherapy response and, Biologic therapy, for prostate cancer, 1329
2145 Biomarkers. See Tumor markers
Appalachia, breast and cervical cancer mortality in, 1593 Biopsy
Argyrophilic cell hyperplasia, duodenal carcinoids and, endometrial, diagnostic yield of, 1765
963 image-guided core-needle, in lymphoma, 647
Arterial embolization, with arterial infusion chemother- lymph node
apy, for pancreatic cancer, 303 image-guided core-needle, in Hodgkin’s disease, 647
Arterial infusion chemotherapy, for pancreatic cancer, sentinel node
303 in breast cancer
Ascorbic acid, accumulation of, in squamous cell carci- computer simulations for, 2187
noma, 17] false negative, after preoperative chemotherapy,
Asian Americans, screening for breast and cervical cancer 2187
in, 696 in melanoma
Asians frozen section analysis of, 1720
breast cancer in, BRCA/ mutation and, 811 patient selection for, 453
nasal-type natural killer/T-cell and natural killer pre- percutaneous needle, of musculoskeletal masses, 2677
cursor lymphoma in, 2106 prostate
in U.S., gastric cancer in, clinical features and survival
detailed mapping of disease foci in, 1800
in, 1183
postbrachytherapy, disease and treatment effects on,
Assessment tool(s)
1829
McGill Quality of Life Questionnaire, 1854
single microscopic focus on, postoperative outcome
M.D. Anderson Symptom Inventory, 1634
and, 1810
for symptom distress, 1634
Bipolar symptoms, interferon-alpha-2b and, 356
Astrocytoma, pathologic classification of, 1569
Bisphosphonates, for skeletal complications, in breast
Auriculotemporal syndrome, botulinum toxin for, 1659
cancer, 363
Australia, melanoma in, time trends of, 1269
Blacks
Avascular necrosis of femoral head, in interferon-treated
bladder cancer in, stage at diagnosis of, 1349
chronic myeloid leukemia, 1482
breast cancer outcome in, 2202
Bladder cancer
B chemoradiotherapy for, 1089
B7 molecules, T-cell proliferation and, in B-cell chronic management and outcome in, in Canada, population-
lymphoproliferative disorders, 1259 based study of, 142
Basal cell carcinoma, clustering of, 1012 p21, p53 and mdm2 in, prognosis and, 619
B-cell chronic lymphocytic leukemia, CD44 and intercel- smoking and, 630
lular adhesion molecule-1 in, during interferon stage at diagnosis of, race and, 1349
therapy, 1474 Blastoma, pleuropulmonary, management and prognosis
B-cell chronic lymphoproliferative disorders, T-cell pro- of, 1396
liferation in, B7 molecules and, 1259 Blood tests, fecal occult, guaiac vs. immunochemical,
B-cell lymphoma sensitivity of, 46
cutaneous Body mass index, breast cancer risk and, 369
anti-CD20 antibody for, 1835 Body weight, breast cancer risk and, 369
central nervous system involvement in, 913 Bone, myogenic tumors of, post-transplant, Epstein-Barr
telomerase activity in, 445 virus in, 467
bel-2 Bone disease, in metastatic breast cancer, predictors of,
in breast cancer, chemotherapy response and, 2145 363
in renal cell carcinoma, DNA content and, 1065 Bone marrow transplantation
BCNU, resistance to, transforming growth factor-B1- for chronic myeloid leukemia, in younger patients,
binding protein and, 850 1647
Benign breast disease for HIV-associated non-Hodgkin’s lymphoma, 680
cancer risk with hormone replacement therapy and, Bone metastasis
2046 in metastatic breast cancer, predictors of, 363
relaxin-like factor in, 2161 in soft tissue sarcoma, routine scintigraphy for, 1726
Subject Index—Volume 89 bmv
Bone resorption, in oral cancer, interleukin-6 enhance- lobular, hormone replacement therapy and, 1867 (let-
ment of, 1966 ter)
Bone scintigraphy, in soft tissue sarcoma staging, 1726 lymphatic mapping in, 236
Botulinum toxin, for Frey syndrome, 1659 lymph node metastasis in
Brachytherapy. See also Radiation therapy computer simulations of, 2527
with intraluminal iridium-192, for biliary papillomato- sentinel vs. nonsentinel node, 574
sis, 69 mortality in, in Appalachian women, 1593
for prostate cancer, 135 node-negative, DNA content of, prognostic value of,
effects of on biopsy results, 1829 1748
prostatourethral-rectal fistula after, 2085 pegylated liposomal doxorubicin (Doxil) for, 1037
Brain. See also under Cerebral persistent impact of on functional health status, 2176
Brain metastasis postmastectomy irradiation for, axillary node extran-
from prostate cancer, 706 (letter) odal soft tissue extension and, 223 (ietter)
from unknown primary, 1095 psychosocial group intervention for, in Japan, 1026
Brain stem tumors, pathologic classification of, 1569 refractory, paclitaxel for, 2195
Brain tumors relaxin-like factor in, 2161
brain stem, pathologic classification of, 1569 screening for
glioblastoma multiforme, trofosfamide and etoposide in Asian American and Pacific Islanders, 696
for, 2131 CEA immunoscintigraphy with, 104
glioma as second primary, 1999
sentinel/completion lymphadenectomy for, 236
carmustine resistance in, transforming growth fac-
tor-81-binding protein and, 850 sentinel node biopsy in, false negative, after preopera-
venous thromboembolism in, 640 tive chemotherapy, 2187
serum CYFRA 21-1 in, 1285
BRCAI heterozygotes, premalignant ovarian changes in,
skeletal complications in, predictors of, 363
383
survival in, in U.S. vs. Europe, 893
BRCAI mutation, breast cancer and, in Asian women, 811
tamoxifen for, uterine cancer surveillance after, 800
BRCA2, allelic imbalance at, in nonsmall cell lung cancer,
treatment of
1933
less than definitive, recurrence and mortality and,
Breast
1739
cystosarcoma phyllodes of, treatment of, 1502
in older women, 561
fiberoptic ductoscopy of, 1512
weight, body mass index and tissue density and, 369
tissue density of, cancer risk and, 369
Breast conserving surgery, in older women, 561
Breast cancer
Breast disease, benign
advanced, doxorubicin and paclitaxel for, 2169
cancer risk with hormone replacement therapy and,
axillary tumor free nodes in, number of, prognosis and,
2046
213 (letter)
relaxin-like factor in, 2161
biopsy in, percutaneous, imaging-histologic discor-
Bronchoscopy, fluorescence, in lung cancer detection,
dance in, 2538
2468
BRCAI mutation and, in Asian women, 811
Bryostatin-1, for metastatic renal cell carcinoma, 615
CEA immunoscintigraphy for, 104
chemotherapy response in, apoptosis and cellular pro-
liferation and, 2145 C
COX-2 in, 2637 Ca** /calmodulin-dependent protein kinase IV, in hepa-
cyclophosphamide-doxorubicin vs. cyclophospha- tocellular carcinoma, 1910
mide-methotrexate-5-fluorouracil for, 2521 CA 19-9, in pancreatic cancer, vs. tissue polypeptide spe-
ductal in situ cific antigen, 83
HER-2/neu amplification and p53 mutation in, 2153 CA 125, in fallopian tube cancer, prognosis and, 1555
local recurrence of, outcome in and factors affecting, Cadherins
2323 (letter) in cervical cancer, 2053
estrogen receptor-a/8 MRNA expression in, PCR anal- in ulcerative colitis—associated colorectal cancer, 733
ysis of, 1732 Calcium channel blockers, cancer risk and mortality with,
gastric metastasis in, presentation, endoscopic features 165
and treatment of, 2214 CaM-kinase IV, in hepatocellular carcinoma, 1910
hereditary prostate cancer and, 1315 Canada
hormone replacement therapy and, in benign breast bladder cancer management and outcome in, popula-
disease, 20246 tion-based study of, 142
ICI 182,780 (Faslodex) for, 817 cancer incidence rates and socioeconomic status in, vs.
intratumoral injection of dendritic cells for, 2646 in U.S., 901
bmvi CANCER December 15, 2000 / Volume 89 / Number 12
Cancer incidence Cerebral metastasis
socioeconomic status and, in Canada vs. U.S., 901 from prostate cancer, 706 (letter)
in very elderly, in Netherlands, 1121 from unknown primary, 1095
Cancer of the Liver Italian Program (CLIP) score, 2266 Cervical cancer
Cancer of unknown primary site, paclitaxel-carboplatin- cadherins in, 2053
etoposide for, 2655 early invasive adenocarcinoma, histopathology of, 1048
Cancer pain consultation, outcome of, 920 in Ivory Coast, 653
Cancer patient, personal account of, 229 mortality in, in Appalachian women, 1593
Cancer risk, with calcium channel blockers, 165 non-squamous cell, increasing incidence of, in Nor-
Cancer survival, in U.S. vs. Europe, 893 way, 1291
Cancer treatment, compliance with, use of alternative radiotherapy for, high growth fraction at 9 Gy in, prog-
therapies and, 873 nosis and, 1526
Carboplatin screening for
for cancer of unknown primary site, 2655 in Asian American and Pacific Islanders, 696
for metastatic retinoblastoma, 2117 direct visual inspection vs. Pap smear for, 826
with radiotherapy in resource-poor settings, 826
for head and neck cancer, 2099 squamous cell, p53 and p21 in, 1300
for nonsmall cell lung cancer, 534 survival in, in U.S. vs. Europe, 893
Carcinoembryonic antigen, isolated elevation of, in colo- Cervical dysplasia, folate, homocysteine, vitamin B,. and
rectal cancer, radioimmunoguided surgery for, cysteine as markers for, 376
1692 Cervix, direct visual inspection of, vs. Pap smear, 826
Carcinoembryonic antigen immunoscintigraphy, for c-ets], in endometrial cancer, 2059
breast cancer, 104 Chemoembolization
Carcinoembryonic antigen mRNA, in colorectal cancer, hepatic arterial
prognosis and, 970 with percutaneous microwave coagulation therapy,
Carcinoids, multiple duodenal, 963 1245
Carmustine, resistance to, transforming growth factor- preoperative, in hepatocellular carcinoma, 2606
61-binding protein and, 850 for pancreatic cancer, 303
Carotid body paraganglioma, vs. schwannoma with an- Chemoradiotherapy. See also Chemotherapy; Radiation
giosarcoma, 1577 therapy
Cartilaginous tumors, connective tissue growth factor in, for bladder cancer, 1089
1466 for cerebral lymphoma, 1359
Catalase, in prostatic intraepithelial neoplasia and can- for esophageal cancer, 946, 2144 (erratum)
cer, 123 for extrahepatic biliary tract recurrence of gastric can-
Catenin, in ulcerative colitis—associated colorectal can- ceive
cer, 733 for head and neck cancer, 2099
Cathepsin B for nonsmall cell lung cancer, 534
in chondrosarcoma, 995 for oral/oropharyngeal cancer, 939
in lymph nodes, in nonsmall lung cancer, prognosis for pancreatic cancer, vs. resection, as initial therapy,
and, 2282 314
Cathepsins, in early stage gastric cancer, 482 for pediatric nasopharyngeal cancer, 690
CD44 for retinoblastoma, with metastasis, 2117
in non-Hodgkin’s lymphoma and chronic lymphocytic Chemosensitivity testing, for hepatic arterial infusion
leukemia, during interferon therapy, 1474 chemotherapy, 288
in ulcerative colitis-associated colorectal cancer, 733 Chemotherapy. See also specific drugs
Cell adhesion molecules arterial infusion, for pancreatic cancer, 303
in non-Hodgkin’s lymphoma and B-cell chronic lym- for breast cancer, 817, 1037
phocytic leukemia, during interferon therapy, in advanced disease, 2169
1474 in older women, 561
in ulcerative colitis—-associated colorectal cancer, 733 in refractory disease, 2195
Cellular proteases, in chondrosarcoma, 995 response to, apoptosis and cellular proliferation and,
Central Europe, melanoma in, time trends of, 1269 2145
Central nervous system involvement, in cutaneous B-cell for cancer of unknown primary site, 2655
lymphoma, 913 for colorectal cancer, 1699
Central neurocytoma, 1111 for fallopian tube cancer, 2076
c-erbB-3, in verrucous oral cancer, 2597 for glioblastoma multiforme, 2131
Cerebral lymphoma, radiation therapy with/without che- for gynecologic cancer, quality of life and, 1402
motherapy for, 1359 for head and neck cancer, 2587
Subject Index—Volume 89 bmvii
hepatic arterial infusion, thymidylate synthase quanti- CHOP regimen, for cerebral lymphoma, with radiation
tation and in vitro chemosensitivity testing for, therapy, 1359
288 Choriocarcinoma, cyclin E in, 673
for hepatoblastoma presenting with lung metastasis, Chromosome 3p23, loss of heterozygosity at, in colorectal
1845 cancer, prognosis and, 1220
for hepatocellular carcinoma, 750 Chronic duodenitis, multiple carcinoids and endocrine
for hepatoma, 983 cell micronests in, 963
for lung cancer, 89, 516, 543, 750, 763, 769, 774, 1714 Chronic hepatitis C
in elderly, 328, 1953 hepatocellular carcinoma and, incidence-related fac-
in induction therapy, 1946 tors in, 53
in metastatic disease, 2622 transforming growth factor-a mRNA in, 977
p53 mutations and, 769 Chronic leukemia. See Leukemia
with radiotherapy, 534 Chronic lymphoproliferative disorders, B-cell, T-cell pro-
for maxillary sinus cancer, 1925 liferation in, B7 molecules and, 1259
for melanoma, with interferon-a, 2630 Cigarette smoking. See Smoking
nausea and vomiting in, ganisetron vs. ondansetron Cisplatin
for, 2301 for esophageal cancer, with radiation therapy, 946
for neuroblastoma, with granulocyte-colony stimulat- for hepatoblastoma presenting with lung metastasis,
ing factor, 2122 1845
for lung cancer
for osteosarcoma, reproductive function after, 1961
in elderly, 1953
for ovarian cancer, in Stage III/IV disease, 1547
with gemcitabine, 1714
for pancreatic cancer, 1706
in induction therapy, 1946
patient’s experience of, 229
in metastatic disease, 2622
for peritoneal mesothelioma, 1279
with paclitaxel and ifosfamide, 774
pharmacokinetic modulating, for hepatic colorectal
for melanoma, with interferon-a, 2630
metastasis, 1228
for metastatic retinoblastoma, 2117
preoperative, for oral/oropharyngeal cancer, with con-
for neuroblastoma, with granulocyte-colony stimulat-
current chemoradiotherapy, 939
ing factor, 2122
for prostate cancer, 1824
for ovarian cancer, 1547
in weekly 1-hour infusion, 431, 1412 (erratum)
for pancreatic cancer, arterial infusion of, 303
with radiotherapy. See Chemoradiotherapy
for peritoneal mesothelioma, 1279
reduced efficacy of, after pneumoperitoneum, 262
for soft tissue sarcoma, 177
for retinoblastoma, with metastasis, 2117
CLIP score, 2266
for soft tissue sarcoma, 177
c-MYC,in nodular melanoma, 97
Chest radiography
Colorectal cancer
in lung cancer screening. See Lung cancer, screening
carcinoembryonic antigen mRNA in, prognosis and,
for
970
radiation exposure in, 2457 classification of by tumor edge morphology, 1901
Children. See also specific cancers
COX-2 in, 2637
glioblastoma multiforme in, trofosfamide and etopo- familial, Swedish cohort study of, 741
side for, 2131 5-fluorouracil for, small intestinal toxicity of, 711 (let-
leukemia in. See Leukemia
ter)
lymphoma in, pesticide exposure and, 2315 guaiac vs. insmunochemical occult blood test for, sen-
metastatic retinoblastoma in, chemoradiotherapy for, sitivity of, 46
ZUE7 hepatic metastasis in
nasopharyngeal cancer in, chemoradiotherapy for, 680 blood flow in, 1236
neuroblastoma in, granulocyte-colony stimulating fac- distribution of, 285
tor with chemotherapy for, 2122 fibrous pseudocapsule of, 257
salivary gland tumors in, Epstein-Barr virus in, 463 microwave coagulation therapy for, 276
Chinese. See also Asians pharmacokinetic modulating chemotherapy for,
Chinese staging system, for nasopharyngeal cancer, vs. 1228
UICC system, 242 tumor thickness and, 35
Chondroma, connective tissue growth factor in, 1466 vascular endothelial growth factor and, 488
Chondrosarcoma with high-frequency microsatellite instability, clinico-
cathepsin B in, 995 pathology of, 2025
connective tissue growth factor in, 1466 loss of heterozygosity at 3p23 in, prognosis and, 1220
urokinase plasminogen activator in, 995 metastatic, 9-aminocamptothecin for, 1699
bmviii CANCER December 15, 2000 / Volume 89 / Number 12
offspring of women with, lymphoma risk in, 741 Cystectomy, for bladder cancer, population-based study
paclitaxel radiosensitizing effect in, p53 and, 1893 of, 142
radioimmunoguided surgery for, 1692 Cysteine, as cervical dysplasia marker, 376
recurrent, with isolated CEA elevation, radioimmu- Cysteine proteases, in early stage gastric cancer, 482
noguided surgery for, 1692 Cystosarcoma phyllodes of breast, treatment of, 1502
survival in, in U.S. vs. Europe, 893 Czechoslovakia, lung cancer screening in, 2363
tumor thickness in, prognosis and, 35
ulcerative colitis—associated, cell adhesion molecules D
in, 733
D13S171, allelic imbalance at, in nonsmall cell lung can-
Community income, cancer incidence and, in Canada vs.
cer, 1933
US., 901
Dacarbazine, with interferon-a, for melanoma, 2630
Complementary medicine, compliance with standard
Deep vein thrombosis, gliomas and, 640
treatment and, 873
Deleted colon carcinoma, in ulcerative colitis—associated
Compliance, with standard treatment, use of alternative
colorectal cancer, 733
therapies and, 873
Delirium, in advanced cancer, prognostic impact of, 1145
Computed tomography
Dendritic cells, intratumoral injection of, 2646
in Hodgkin’s disease, correlation of with lymphangiog- Dendritic cell sarcoma, of neck, 664
raphy and Ga-67 SPECT, 1371 Depression
in lung cancer screening, 2457, 2474. See also Lung interferon-alpha-2b and, 356
cancer, screening for after successfully treated lung cancer, 1172
in Japan, 2485 Developing countries. See also specific countries
radiation exposure in, 2457 cost-effective early detection programs in, 475
in ovarian cancer, in surgical outcome prediction, 1532 Dexamethasone, low-dose oral, for prostate cancer, 2570
in pancreatic cancer, cost analysis for, 1917 Diet
Computer simulations, of lymph node metastasis, in as cervical dysplasia marker, 376
breast cancer, 2527 gastric cancer survival and, 1205
Congenital sacrococcygeal teratoma, DNA ploidy in, 932 DNA content
Connective tissue growth factor, in cartilaginous tumors, of breast cancer, prognostic value of, 1748
1466 of colorectal cancer, with high-frequency microsatellite
Consultation, cancer pain, outcome of, 920 instability, 2025
Counseling, for breast cancer patients, in Japan, 1026 of congenital sacrococcygeal teratoma, 932
COX-2 of gastric lymphoma, 12
in prostate cancer, 589 of renal cell carcinoma, p53 and bcl-2 and, 1065
in pulmonary, colonic and mammary tumors, 2637 Docetaxel
Cutaneous B-cell lymphoma for hepatoma, 983
anti-CD20 antibody for, 1835 lymphopenia and, 1380
for nonsmall cell lung cancer, 516
central nervous system involvement in, 913
weekly administration of, in elderly, 328
Cutaneous lymphoma, interferon-a for, 1603
with paclitaxel, weekly administration of, 2309
Cy5.5 complex, in immunofluorescent tumor localiza-
Doxil, for breast cancer, 1037
tion, 1134
Doxorubicin
Cyclin-dependent kinases, in gastric cancer, prognosis
for breast cancer, 2169
and, 2247
with cyclophosphamide, 2521
Cyclin E, in gestational trophoblastic disease, 673
pegylated liposomal, 1037
Cyclooxygenase-2
for cerebral lymphoma, with radiation therapy, 1359
in prostate cancer, 589
for hepatoblastoma presenting with lung metastasis,
in pulmonary, colonic and mammary tumors, 2637
1845
Cyclophosphamide
for neuroblastoma, with granulocyte-colony stimulat-
for breast cancer
ing factor, 2122
with doxorubicin, 2521 for peritoneal mesothelioma, 1279
with methotrexate and 5-fluorouracil, 2521 Ductal carcinoma in situ. See also Breast cancer
for cerebral lymphoma, with radiation therapy, 1359 HER-2/neu amplification and p53 mutation in, 2153
for metastatic retinoblastoma, 2117 local recurrence of, outcome in and factors affecting,
for neuroblastoma, with granulocyte-colony stimulat- 2323 (letter)
ing factor, 2122 Ductoscopy, fiberoptic, for nipple discharge, 1512
CYFRA 21-1 Duodenal carcinoids, endocrine cell micronests and, 963
in breast cancer, 1285 Duodenitis, chronic, multiple carcinoids and endocrine
in esophageal cancer, 1413 cell micronests in, 963
Subject Index—Volume 89 bmix
E CYFRA 21-1 in, 1413
fragile histidine triad gene in, 5
Early Lung Cancer Action Project, 2474
initial lymph node metastasis in, localization of, 1869
E-cadherin, in ulcerative colitis—associated colorectal
invasiveness of, Ets-1 and, 1670
cancer, 733
serum p53 antibody in, 1677
Elderly
squamous cell
age limits for, in non-Hodgkin’s lymphoma, 2667
KAI1/CD82 in, 955
breast cancer in, treatment of, 561
neoadjuvant chemoradiotherapy for, 946, 2144 (erra-
cancer incidence in, in Netherlands, 1121
tum)
nonsmall cell lung cancer in, chemotherapy for, 328,
superficial, ductal involvement in, 248
1953
Esophagogastric junction adenocarcinoma, lymph node
Embolization
micrometastasis and tumor cell microinvolve-
hepatic arterial
ment in, 1874
with percutaneous microwave coagulation therapy, Estramustine, for prostate cancer, 1824
1245 Estrogen receptor-a/8 mRNA expression, in breast can-
preoperative, 2606 cer, PCR analysis of, 1732
transcatheter arterial, with arterial infusion chemo- Estrogen replacement therapy
therapy, for pancreatic cancer, 303 in benign breast disease, cancer risk and, 2046
Emotional status lobular breast cancer and, 1867 (letter)
of breast cancer patients Etoposide
in Japan, 1026 for cancer of unknown primary site, 2655
persistent changes in, 2176 for glioblastoma multiforme, 2131
depression after successfully treated lung cancer, 1172 for metastatic retinoblastoma, 2117
in gynecologic cancer, with extensive chemotherapy, for neuroblastoma, with granulocyte-colony stimulat-
1402 ing factor, 2122
personal account of, 229 for nonsmall cell lung cancer
in prostate cancer, before/after radiation therapy, 1322 in elderly, 1953
in successfully treated lung cancer, 1172 in induction therapy, 1946
Enchondroma, connective tissue growth factor in, 1466 with oral administration, 543
Endocrine cell micronests, in chronic duodenitis, 963 for soft tissue sarcoma, 177
Endometrial cancer Ets-1
c-ets] in, 2059 in esophageal cancer, tumor invasiveness and, 1670
microsatellite instability in in meningioma, 2292
analysis at 10q25-q26 and, 1773 Europe. See also specific countries
clinical significance of, 1758 cancer survival in, vs. in U.S., 893
surveillance for, in tamoxifen-treated breast cancer Ewing’s sarcoma
INK4A deletion in, prognosis and, 783
survivors, 800
p53 in, prognosis and, 783
survival in, in U.S. vs. Europe, 893
Extrahepatic bile ducts, noninvasive/minimally invasive
tissue sampling in, diagnostic yield of, 1765
. papillary carcinoma of, 508
Endometrial sampling, diagnostic yield of, 1765
Extremity osteosarcoma, chemotherapy for, reproductive
Endostatin, in antiangiogenic gene therapy, 1181
function after, 1961
Enzymes, antioxidant, in prostatic intraepithelial neopla-
sia and cancer, 123
Epidermal growth factor, salivary, mucositis and, in oro- F
pharyngeal radiation therapy, 2258
Fallopian tube cancer
Epirubicin
CA 125 in, prognosis and, 1555
for nonsmall cell lung cancer, 89 treatment and prognosis in, 2076
for ovarian cancer, 1547 Familial medullary thyroid carcinoma syndrome, RET
Eppendorf pO. measurements, in prostate cancer, stage mutation carriers of, thyroidectomy for, 863
and patient age and, 2018 Familial prostate cancer, breast and gastric cancer and,
Epstein-Barr virus 3315
in pediatric salivary gland tumors, 463 Fas ligand, circulating soluble, in gastric cancer, 2560
in post-transplant myogenic tumors of bone, 467 Faslodex, for breast cancer, 817
ERBB-2 in ovarian tissue, in BRCA/ heterozygotes, 383 Fatigue, in prostate cancer, before/after radiation ther-
Errata, 473, 1412, 2144 apy, 1322
Esophageal cancer FDG positron emission tomography, in melanoma, 1019
adenocarcinoma, lymph node micrometastasis and tu- Fecal occult blood tests, guaiac vs. immunochemical,
mor cell microinvolvement in, 1874 sensitivity of, 46
bmx CANCER December 15, 2000 / Volume 89 / Number 12
Femoral head, avascular necrosis of, in interferon-treated Gallium-67 SPECT, in Hodgkin’s disease, correlation of
chronic myeloid leukemia, 1482 with lymphangiography and CT, 1371
Fertility Ganglioneuroblastoma, nodular, prognostic classification
after chemotherapy, for osteosarcoma, 1961 of, 1150
preservation of, for ovarian germ cell tumors, 391 Ganisetron, for chemotherapy-induced nausea and vom-
'SF-fluoro-2-deoxy-D-glucose PET, delayed, in pancre- iting, 2301
atic cancer, 2547 Gastrectomny
FHIT, in esophageal cancer, 5 early and late recurrence after, 255
Fiberoptic ductoscopy, for nipple discharge, 1512 with prophylactic radical lymphadenectomy, 1425
Fibrillary astrocytoma, pathologic classification of, 1569 Gastric cancer
Fistula, prostatourethral-rectal, after brachytherapy, 2085 in Asian patients in U.S., clinical features and survival
Flow cytometry in, 1183
in breast cancer, prognostic value of, 1748 biliary obstruction in, chemoradiation for, 29
in colorectal cancer, with high-frequency microsatellite circulating soluble Fas ligand in, 2560
instability, 2025 differentiated type early, gastric type mucin expression
in congenital sacrococcygeal teratoma, 932 in, 724
in gastric lymphoma, 12 early stage, cathepsins in, 482
in renal cell carcinoma, p53 and bcel-2 and, 1065 hereditary prostate cancer and, 1315
Fluconazole, oral, for fungal infection prophylaxis, 1611 in Japan vs. U.S., 2237, 2555
Fluorescence bronchoscopy, in lung cancer detection, p27*'?' in, prognosis and, 1684, 2247
2468 P-glycoprotein in, p53 and, 21
2-Fluorine-18, 2-fluoro-2-deoxy-,,-glucose PET scanning, prophylactic radical lymphadenectomy with gastrec-
in melanoma, 1019 tomy for, 1425
5-Fluorouracil
surgery for. See Gastrectomy
for breast cancer, with cyclophosphamide and metho- survival in
trexate, 2521
premorbid diet and, 1205
for esophageal cancer, with radiotherapy, 946
in U.S. vs. Europe, 893
for head and neck cancer, with radiotherapy, 939
well vs. poorly differentiated, pathology and prognosis
hepatic arterial infusion of, thymidylate synthase
of, 1418
quantitation and in vitro chemosensitivity test-
Gastric lymphoma
ing for, 288
DNA content of, 12
for hepatic colorectal metastasis, 1228
soluble intercellular adhesion molecules-1 in, progno-
for pancreatic cancer, via arterial infusion, 303
sis and, 1387
for renal cell carcinoma, with interleukin-2 and subcu-
in Turkey, 12
taneous interferon-a, 597
Gastric metastasis, in breast cancer, presentation, endo-
small intestinal toxicity of, 711 (letter)
scopic features and treatment of, 2214
Folate, as cervical dysplasia marker, 376
Gastric type mucin expression, in differentiated type
Follicular dendritic cell sarcoma, of neck, 664
early gastric carcinoma, 724
Foregut carcinoids, duodenal, 963
Gemcitabine
Fotemustine, with interferon-a, for melanoma, 2630
for hepatocellular carcinoma, 750
Fractures, pathologic, in breast cancer, predictors of, 363
for lung cancer, 516, 543
Fragile histidine triad gene, in esophageal cancer, 5
with cisplatin, 1714
France, gallbladder cancer incidence trends and manage-
with etoposide, 543
ment in, 757
Frey syndrome, botulinum toxin for, 1659 in metastatic disease, 2622
Frozen section analysis, of sentinel nodes, in melanoma, with vinorelbine, 763
1720 for pancreatic cancer, with leucovorin-modulated UFT,
Functional health status 1706
in breast cancer, persistent changes in, 2176 Gene therapy
symptom distress and, 1634 antiangiogenic, 1181
Fungal infections, neutropenic, oral fluconazole prophy- for prostate cancer, 1329
laxis for, 1611 Germany
lung cancer histopathology in uranium workers in,
2613
G
lung cancer screening in, cost-effectiveness of, 2489
Gabapentin, for interferon-alpha-2b-associated mood in- thyroid cancer in, 1
stability, 356 patterns of care for, 192
Gallbladder cancer, incidence trends and management Germ cell tumors, ovarian, conservative surgery for, 391
of, in France, 757 Gestational trophoblastic disease, cyclin E in, 673
Subject Index—Volume 89 bmxi
Gleason grading, of prostate cancer, Web-based tutorial Hepatitis C
for, 1818 hepatocellular carcinoma and, incidence-related fac-
Glioblastoma multiforme, trofosfamide and etoposide tors in, 53
for, 2131 transforming growth factor-a mRNA in, 977
Glioma Hepatoblastoma, presenting with lung metastases, 1845
carmustine resistance in, transforming growth factor- Hepatocellular carcinoma
B1-binding protein and, 850 Ca** /calmodulin-dependent protein kinase IV in, 1910
venous thromboembolism in, 640 in chronic hepatitis C, incidence-related factors in, 53
Glutathione, in pancreatic cancer, 1440 early vs. late recurrence of, risk and prognostic factors
Glyceraldehyde-3-phosphate dehydrogenase, in renal for, 500
cell carcinoma, 152 gemcitabine for, 750
Grading, of prostate cancer, Web-based tutorial for, 1818 Helicobacter spp. and, 1431
Granulocyte—colony stimulating factor hepatic arterial chemoembolization for
for neuroblastoma, 2122 with percutaneous microwave coagulation therapy,
for nonsmall cell lung cancer, 516 1245
Group therapy, for breast cancer patients, in Japan, 1026 preoperative, 2606
Gustatory sweating, botulinum toxin for, 1659 hepatic arterial infusion chemotherapy for, thymidy-
Gynecologic cancer. See also specific types late synthase quantitation and in vitro chemo-
chemotherapy for, quality of life and, 1402 sensitivity testing for, 288
HFE mutations in, surgical outcome and, 297
H nuclear factor «B in, 2266
p16 inactivation in, 60
Head and neck cancer
p53 in, in India, 2322 (letter)
bone invasion in, interleukin-6 enhancement of, 1966
staging of, 2266
carboplatin with radiation therapy for, 2099
transforming growth factor-a mRNA in, 977
induction paclitaxel for, 2587
Hepatoma
preoperative chemotherapy followed by chemoradio-
hepatic arterial infusion chemotherapy for, thymidy-
therapy for, 939
late synthase quantitation and in vitro chemo-
radiation therapy for, mucositis in, salivary epidermal
sensitivity testing for, 288
growth factor and, 2258
2-methoxyestradiol vs. docetaxel vs. paclitaxel for, 983
survival in, in India, 437
HER-2/neu, in ductal carcinoma in situ, 2153
Head and neck sarcoma, prognostic factors in, 868
Hereditary medullary thyroid carcinoma syndrome, RET
Health insurance, breast cancer outcome and, 2202
mutation carriers of, thyroidectomy for, 863
Health maintenance organizations, breast cancer out-
Hereditary prostate cancer, breast and gastric cancer
come and, 2202
and, 1315
Healthy People 2000, breast and cervical cancer screen-
Heterogeneous nuclear ribonucleoprotein A2/B1, in lung
ing in Asian American and Pacific Islanders and,
696 cancer screening, 2465
HFE mutations, in hepatocellular careinoma, surgical
Helicobacter spp., hepatocellular carcinoma and, 1431
Heparin, post-pneumoperitoneum survival time and, 262 outcome and, 297
Hip, osteonecrosis of, in interferon-treated chronic my-
Hepatic arterial chemoembolization
with percutaneous microwave coagulation therapy, eloid leukemia, 1482
HIV infection, non-Hodgkin’s lymphoma in, stem cell
1245
preoperative, in hepatocellular carcinoma, 2606 transplant for, 680
Hepatic arterial infusion chemotherapy, thymidylate syn- HMOs, breast cancer outcome and, 2202
thase quantitation and in vitro chemosensitivity Hodgkin’s disease. See also Lymphoma
testing for, 288 correlation of Ga-67, SPECT, CT and lymphangiogra
Hepatic failure, raltitrexed and, 890 phy in, 1371
Hepatic metastasis, in colorectal cancer epidemiology of, in Southern Taiwan, 1586
blood flow in, 1236 image-guided core-needle biopsy in, 647
distribution of, 285 survival in, in U.S. vs. Europe, 893
fibrous pseudocapsule of, 257 Homocysteine, as cervical dysplasia marker, 376
microwave coagulation therapy for, 276 Hormone receptor status
pharmacokinetic modulating chemotherapy for, 1228 in breast cancer, PCR analysis of, 1732
tumor thickness and, 35 in ovarian cancer, prognosis and, 1783
vascular endothelial growth factor and, 488 Hormone replacement therapy
Hepatic resection, outcome of, HFE mutations and, 297 in benign breast disease, cancer risk and, 2046
Hepatitis B, hepatocellular carcinoma and, in India, 2322 lobular breast cancer and, 1867 (letter)
(letter) Hospice care, morphine in, 220 (letter)
bmxii CANCER December 15, 2000 / Volume 89 / Number 12
Human immunodeficiency virus’ infection, non- Institute of Medical Informatics, patterns of care for thy-
Hodgkin’s lymphoma in, stem cell transplant roid cancer in Germany, 192
for, 680 Insulin-like molecule 3, in normal vs. neoplastic breast
Human pancreatic ribonuclease 1, in pancreatic cancer, tissue, 216]
1252 Insurance, breast cancer outcome and, 2202
Human papillomavirus DNA testing, vs. Pap smear, 826 Intercellular adhesion molecule-1, in non-Hodgkin’s
Human papillomavirus infection, cervical cancer and, lymphoma and chronic lymphocytic leukemia,
basal cell tetrasomy and p53/p21 expression during interferon therapy, 1474
and, 1300 Interferon-a
Human tumor colony-forming assay, for hepatic arterial for chronic myeloid leukemia
infusion chemotherapy, 288 avascular necrosis of femoral head and, 1482
Hydatidiform mole, cyclin E in, 673 in younger patients, 1647
Hypercalcemia, in breast cancer, predictors of, 363 for lymphomatoid papulosis, 1603
Hypereosinophilic syndrome, lymphomatoid papulosis for melanoma
and, 2138 with cisplatin-dacarbazine-fomustine, 2630
Hypergastrinemia, duodenal carcinoids and, 963 in recurrence, 1498
Hyperthermia for metastatic osteosarcoma, with retinoic acid, 2661
for peritoneal mesothelioma, 1279 for renal cell carcinoma
with radiation therapy, for prostate cancer, 399 with 5-fluorouracil and interleukin-2, 597
Hypomethylation, in acute lymphoblastic leukemia- with infusional interleukin-2 and 5-fluorouracil, 597
associated leukoencephalopathy, 925 Interferon-alpha-2b, for melanoma, mania and bipolar
Hypopharyngeal cancer. See also Head and neck cancer syndromes and, 356
survival in, in India, 437 Interleukin-2, plus 5-fluorouracil and subcutaneous in-
Hypoxia, in prostate tumors, stage and patient age and, terferon-a, for renal cell carcinoma, 597
2018 Interleukin-6, in oral cancer, enhanced bone invasion
Hysterectomy, pelvic nerve plexus trauma during, 834, and, 1966
International Association for the Study of Lung Cancer
2144 (erratum)
Worldwide Educational Program on Lung Can-
cer, 2331
I International Prognostic Index, for non-Hodgkin’s lym-
phoma, age classification and, 2667
ICI 182,780, for breast cancer, 817
International Union Against Cancer
Ifosfamide
staging system of, for nasopharyngeal cancer, 242
for nonsmall cell lung cancer, with paclitaxel and cis-
Telepathology Consultation Center, 187
platin, 774
Internet-based tutorial, for prostate cancer grading, 1818
for soft tissue sarcoma, 177
Intestinal toxicity, of 5-fluorouracil, 711 (letter)
Image-guided core-needle biopsy, in lymphoma, 647
Iridium-192, intraluminal, for biliary papillomatosis, 69
IMC-C225, inhibition of pancreatic tumor growth by, 74
Italy, lung cancer in, screening for, in smokers, 2345
Immune surveillance, metastatic susceptibility and, 1626
Ivory Coast, cancer incidence in, 653
Immunofluorescence, in tumor localization, using single
chain Fv fragment of monoclonal antibody, 1134
J
Immunoscintigraphy, carcinoembryonic antigen, for
breast cancer, 104 Japan. See also Asians
Immunosuppression, post-transplant, Epstein-Barr virus- gastric cancer in, vs. in U.S., 2237, 2555
associated myogenic tumors of bone and, 467 lung cancer screening in, 2392
Immunotherapy. See also specific agents and modalities computed tomography in, 2485
intratumoral injection of dendritic cells in, 2646 cost-effectiveness of, 2489
for prostate cancer, 1329 psychosocial group intervention for breast cancer pa-
Incidence rates, socioeconomic status and, in Canada vs. tients in, 1026
U.S., 901
India K
head and neck cancer survival in, 437 KAI1/CD82, in esophageal squamous cell carcinoma, 955
hepatocellular carcinoma in, p53 in, 2322 (letter) Kaposi sarcoma, in Ivory Coast, 653
Infertility «B, in hepatocellular carcinoma, 2266
after chemotherapy, for osteosarcoma, 1961 Ki-67
prevention of, in ovarian germ cell tumors, 391 in breast cance1
Inguinal lymphadenectomy, saphenous vein preserva- chemotherapy response and, 2145
tion in, in vulvar cancer, 1520 prognosis and, 1748
INK4A deletion, in Ewing’s sarcoma, prognosis and, 783 in Ewing’s sarcoma, prognosis and, 783